Filtered By:
Infectious Disease: Hepatitis B
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 12797 results found since Jan 2013.
Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years
CONCLUSION: In resource-limited areas where follow-up of HBsAg or other markers is not possible, nucleos(t)ide analog discontinuation can be considered in patients in the early stage, with low baseline hepatitis B virus DNA and ALT levels, after a long consolidation therapy.PMID:37681268 | DOI:10.5152/tjg.2023.22823
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Bilg ül Mete Sibel Y ıldız Kaya Abdurrahman Kaya Ahmet Furkan Kurt Osman Faruk Bayramlar R ıdvan Karaali İlker İnanç Balkan M ücahit Yemişen Re şat Özaras Ne şe Saltoğlu Fehmi Tabak Source Type: research
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients
CONCLUSIONS: Among patients with a previously resolved hepatitis B virus infection on therapy with corticosteroids and conventional synthesis immunosuppressants for kidney disease, hepatitis B virus reactivation was not common and severe, suggesting that universal prophylaxis may not be justified or cost-effective in this clinical setting.PMID:37681265 | DOI:10.5152/tjg.2023.22511
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Pingyang Han Ziqiu Wang Zhaohui Wang Source Type: research
Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years
CONCLUSION: In resource-limited areas where follow-up of HBsAg or other markers is not possible, nucleos(t)ide analog discontinuation can be considered in patients in the early stage, with low baseline hepatitis B virus DNA and ALT levels, after a long consolidation therapy.PMID:37681268 | DOI:10.5152/tjg.2023.22823
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Bilg ül Mete Sibel Y ıldız Kaya Abdurrahman Kaya Ahmet Furkan Kurt Osman Faruk Bayramlar R ıdvan Karaali İlker İnanç Balkan M ücahit Yemişen Re şat Özaras Ne şe Saltoğlu Fehmi Tabak Source Type: research
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients
CONCLUSIONS: Among patients with a previously resolved hepatitis B virus infection on therapy with corticosteroids and conventional synthesis immunosuppressants for kidney disease, hepatitis B virus reactivation was not common and severe, suggesting that universal prophylaxis may not be justified or cost-effective in this clinical setting.PMID:37681265 | DOI:10.5152/tjg.2023.22511
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Pingyang Han Ziqiu Wang Zhaohui Wang Source Type: research
Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years
CONCLUSION: In resource-limited areas where follow-up of HBsAg or other markers is not possible, nucleos(t)ide analog discontinuation can be considered in patients in the early stage, with low baseline hepatitis B virus DNA and ALT levels, after a long consolidation therapy.PMID:37681268 | DOI:10.5152/tjg.2023.22823
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Bilg ül Mete Sibel Y ıldız Kaya Abdurrahman Kaya Ahmet Furkan Kurt Osman Faruk Bayramlar R ıdvan Karaali İlker İnanç Balkan M ücahit Yemişen Re şat Özaras Ne şe Saltoğlu Fehmi Tabak Source Type: research
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients
CONCLUSIONS: Among patients with a previously resolved hepatitis B virus infection on therapy with corticosteroids and conventional synthesis immunosuppressants for kidney disease, hepatitis B virus reactivation was not common and severe, suggesting that universal prophylaxis may not be justified or cost-effective in this clinical setting.PMID:37681265 | DOI:10.5152/tjg.2023.22511
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Pingyang Han Ziqiu Wang Zhaohui Wang Source Type: research
Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years
CONCLUSION: In resource-limited areas where follow-up of HBsAg or other markers is not possible, nucleos(t)ide analog discontinuation can be considered in patients in the early stage, with low baseline hepatitis B virus DNA and ALT levels, after a long consolidation therapy.PMID:37681268 | DOI:10.5152/tjg.2023.22823
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Bilg ül Mete Sibel Y ıldız Kaya Abdurrahman Kaya Ahmet Furkan Kurt Osman Faruk Bayramlar R ıdvan Karaali İlker İnanç Balkan M ücahit Yemişen Re şat Özaras Ne şe Saltoğlu Fehmi Tabak Source Type: research
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients
CONCLUSIONS: Among patients with a previously resolved hepatitis B virus infection on therapy with corticosteroids and conventional synthesis immunosuppressants for kidney disease, hepatitis B virus reactivation was not common and severe, suggesting that universal prophylaxis may not be justified or cost-effective in this clinical setting.PMID:37681265 | DOI:10.5152/tjg.2023.22511
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Pingyang Han Ziqiu Wang Zhaohui Wang Source Type: research
Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years
CONCLUSION: In resource-limited areas where follow-up of HBsAg or other markers is not possible, nucleos(t)ide analog discontinuation can be considered in patients in the early stage, with low baseline hepatitis B virus DNA and ALT levels, after a long consolidation therapy.PMID:37681268 | DOI:10.5152/tjg.2023.22823
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Bilg ül Mete Sibel Y ıldız Kaya Abdurrahman Kaya Ahmet Furkan Kurt Osman Faruk Bayramlar R ıdvan Karaali İlker İnanç Balkan M ücahit Yemişen Re şat Özaras Ne şe Saltoğlu Fehmi Tabak Source Type: research
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients
CONCLUSIONS: Among patients with a previously resolved hepatitis B virus infection on therapy with corticosteroids and conventional synthesis immunosuppressants for kidney disease, hepatitis B virus reactivation was not common and severe, suggesting that universal prophylaxis may not be justified or cost-effective in this clinical setting.PMID:37681265 | DOI:10.5152/tjg.2023.22511
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Pingyang Han Ziqiu Wang Zhaohui Wang Source Type: research
Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study
CONCLUSION: The burden of vaccine-preventable diseases was quite high in HIV-infected patients. Nadir CD4 T-cell counts, peak HIV viral loads, and the number of ART regimen change are significant factors related to vaccination. Considering the low vaccination rates for VPDs, there was a discordance between experts' opinions and real clinical practice in the medical field.PMID:37674339 | DOI:10.3947/ic.2023.0045
Source: Herpes - September 7, 2023 Category: Infectious Diseases Authors: Hye Seong Yunsu Choi Kyoung Hwan Ahn Jun Yong Choi Shin-Woo Kim Sang Il Kim Mee-Kyung Kee Bo Youl Choi Boyoung Park Hak Jun Hyun Jin Gu Yoon Ji Yun Noh Hee Jin Cheong Woo Joo Kim Joon Young Song Source Type: research
Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies
CONCLUSIONS: Eliminating HBV will require interventional strategies to improve diagnostic, linkage-to-care, and treatment coverages. Developing novel therapies will be crucial in further reducing HBV-related mortality and removing HBV as a public health threat.IMPACT AND IMPLICATIONS: This study explores the key developments and optimal intervention strategies needed to achieve WHO hepatitis B elimination targets by 2030 in China. It highlights that China can realise the HBV elimination targets in the incidence by 2025, and by upscaling diagnostic, linkage-to-care, and treatment coverages, up to 2 million lives could poten...
Source: Cancer Control - September 7, 2023 Category: Cancer & Oncology Authors: Rui Li Mingwang Shen Jason J Ong Fuqiang Cui Wenyi Hu Polin Chan Zhuoru Zou Shu Su Hangting Liu Lei Zhang Wai-Kay Seto William C W Wong Source Type: research
Eliminating hepatitis B vaccination disparities for West African immigrants
Vaccine. 2023 Sep 3:S0264-410X(23)01012-5. doi: 10.1016/j.vaccine.2023.08.058. Online ahead of print.ABSTRACTBACKGROUND: Hepatitis B virus (HBV) infection is endemic in West Africa. There has been a significant increase in the Bronx West African (WA) community. To achieve HBV elimination, vaccination of non-immune individuals is important. Unfortunately, vaccine uptake in immigrant populations is at this time very limited.METHODS: An educational program was conducted by medical providers of WA origin in collaboration with local faith-based organizations, after which free HBV screening was offered. Non-immune individuals we...
Source: Vaccine - September 5, 2023 Category: Allergy & Immunology Authors: Jessie A Birnbaum Daniel Guttman Mugdha Parulekar Fatima Omarufilo Emmanuel U Emeasoba Julie Nguyen Oluwadara Tokunboh Jared Coe Matthew J Akiyama Samuel H Sigal Source Type: research
Pharmacophore-Based Virtual Screening and Structural Modification of Novel Benzamide Derivatives as HBV Capsid Assembly Modulators
Biol Pharm Bull. 2023;46(9):1277-1288. doi: 10.1248/bpb.b23-00242.ABSTRACTHepatitis B virus (HBV) infection is the most common cause of death from liver disease worldwide. The use of capsid assembly modulators is considered a prominent strategy for the development of novel anti-HBV therapies. We performed a pharmacophore-based virtual screening strategy, and a benzamide scaffold hit, WAI-5, was chosen for further structural optimization. A series of novel HBV capsid assembly modulators (CAMs) were found. Compared with the lead hit, the representative compounds 11g and 11n exhibited a 10-fold increase in anti-HBV activity w...
Source: Biological and Pharmaceutical Bulletin - September 4, 2023 Category: Drugs & Pharmacology Authors: Yiyang Qin Shengdan Wang Yunwen Wang Yuan Wang Xuefen Tao Hui Zhao Hao Wang Shuang Yu Rong Sheng Source Type: research
